Word: patiently
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...Ultimately, it was even harder to convince outside investors including Goldman Sachs and Daiwa Securities, which had sunk billions of dollars into a Sanyo turnaround, to be patient. The reality is that Sanyo, saddled with $14.7 billion in debt on Sept. 30, according to the company's most recent financial reports, only had the resources to restructure, not revolutionize. With Nonaka gone, analysts expect Sanyo will sell losing divisions while focusing on its best product: rechargeable batteries. That strategy could return Sanyo to profitability, but it won't make the company one that "solves the problems that the world...
...made treatments. Advanced drug trials require a control group, one whose members share key characteristics with those in the experimental arm, but who receive a placebo or another treatment rather than the one under study. According to Bendandi, randomized testing of custom-made vaccines would be meaningless because each patient in the experimental arm receives a different treatment. So he set about proving efficacy in another way. "The course of the study design was the first innovation," writes Dr. Dan Longo in an editorial appearing in the same journal that published Bendandi's study. "Each patient would...
Bendandi's vaccine also faces challenges common to other customized treatments: it's expensive (an estimated $34,000 per patient), it's difficult to make, and not all pharmaceutical companies (which make profits by mass-producing drugs) are able - or willing - to take on the work of producing a different vaccine for every patient. But with three Phase III clinical trials for idiotype vaccines under way in the U.S., and several other types of custom treatments in development (on March 29, an fda advisory committee found "substantial evidence" that a prostate cancer vaccine is effective, increasing the likelihood...
Especially among the researchers developing them. "My trial was designed to have every chance to fail," says Bendandi. "If just one patient relapsed while receiving the vaccine, it would have been over. I would have needed a new job," he jokes. But the Italian-born physician is still working. In a few weeks he starts his new study, which is designed to test the vaccine's effectiveness in follicular lymphoma patients with an especially poor prognosis. Bendandi plans to administer the vaccine to participants until they relapse or die from a cause other than lymphoma. "This time," he says...
...Director Dr. David Rosenthal was surprised to hear about Opal and Face, but said, “Any complaint is a significant complaint,” and told me to call the patient advocate. He then gently lectured me on the silliness of voicing such complaints in an article...